Drug firm Dr Reddy's Laboratories today said it has received establishment inspection report (EIR) from the US health regulator for its custom pharmaceutical services facility at Hyderabad. The facility had undergone audit by the United States Food and Drug Administration (USFDA), Dr Reddy's Laboratories said in a BSE filing. The company has received EIR from the USFDA for the facility, it added. As per USFDA, after the completion of an inspection of a facility, an EIR is issued to a company detailing inspection findings. Shares of Dr Reddy's Laboratories today closed at Rs 2,230.45 per scrip on BSE, down 2.44 per cent.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)